Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND There is an unmet need to develop therapeutic interventions directed at the neurodegeneration that underlies progression in multiple sclerosis. High-dose, pharmaceutical-grade biotin (MD1003) might enhance neuronal and oligodendrocyte energetics, resulting in improved cell function, repair, or survival. The MS-SPI randomised, double-blind, placebo-controlled study found that MD1003 improved disability outcomes over 12 months in patients with progressive multiple sclerosis. The SPI2 study was designed to assess the safety and efficacy of MD1003 in progressive forms of multiple sclerosis in a larger, more representative patient cohort. METHODS SPI2 was a randomised, double-blind, parallel-group, placebo-controlled trial done at 90 academic and community multiple sclerosis clinics across 13 countries. Patients were aged 18-65 years, had a diagnosis of primary or secondary progressive multiple sclerosis fulfilling the revised International Panel criteria and Lublin criteria, a Kurtzke pyramidal functional subscore of at least 2 (defined as minimal disability), an expanded disability status scale (EDSS) score of 3·5-6·5, a timed 25-foot walk (TW25) of less than 40 s, evidence of clinical disability progression, and no relapses in the 2 years before enrolment. Concomitant disease-modifying therapies were allowed. Patients were randomly assigned (1:1) by an independent statistician using an interactive web response system, with stratification by study site and disease history, to receive MD1003 (oral biotin 100 mg three times daily) or placebo. Participants, investigators, and assessors were masked to treatment assignment. The primary endpoint was a composite of the proportion of participants with confirmed improvement in EDSS or TW25 at month 12, confirmed at month 15, versus baseline. The primary endpoint was assessed in the intention-to-treat analysis set, after all participants completed the month 15 visit. Safety analyses included all participants who received at least one dose of MD1003. This trial is registered with ClinicalTrials.gov (NCT02936037) and the EudraCT database (2016-000700-29). FINDINGS From Feb 22, 2017, to June 8, 2018, 642 participants were randomly assigned MD1003 (n=326) or placebo (n=316). The double-blind, placebo-controlled phase of the study ended when the primary endpoint for the last-entered participant was assessed on Nov 15, 2019. The mean time in the placebo-controlled phase was 20·1 months (SD 5·3; range 15-27). For the primary outcome, 39 (12%) of 326 patients in the MD1003 group compared with 29 (9%) of 316 in the placebo group improved at month 12, with confirmation at month 15 (odds ratio 1·35 [95% CI 0·81-2·26]). Treatment-emergent adverse events occurred in 277 (84%) of 331 participants in the MD1003 group and in 264 (85%) of 311 in the placebo group. 87 (26%) of 331 participants in the MD1003 group and 82 (26%) of 311 participants in the placebo group had at least one serious treatment-emergent adverse event. One (<1%) person died in the MD1003 group and there were no deaths in the placebo group. Despite use of mitigation strategies, MD1003 led to inaccurate laboratory results for tests using biotinylated antibodies. INTERPRETATION This study showed that MD1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1003 cannot be recommended for treatment of progressive multiple sclerosis. FUNDING MedDay Pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationKappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Self-citationVirtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Granberg, T., Fan, Q., Treaba, C. A., Ouellette, R., Herranz, E., Mangeat, G., Louapre, C., Cohen-Adad, J., Klawiter, E. C., Sloane, J. A., et al. (2017) · Brain · doi:10.1093/brain/awx247 · Cited by 184
Iron chelation and multiple sclerosis
Weigel, K. J., Lynch, S. G., & LeVine, S. M. (2014) · ASN NEURO · doi:10.1042/an20130037 · Cited by 63
Self-citationRühling, S., Kramer, F., Schmutz, S., Amor, S., Jiangshan, Z., Schmitz, C., Kipp, M., & Hochstrasser, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1353-9 · Cited by 18
Cited by
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Self-citationGraves, J. S., Krysko, K. M., Hua, L. H., Absinta, M., Franklin, R. J. M., & Segal, B. M. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00184-3 · Cited by 260
Self-citationLevy, M. J. F., Garcia-Diaz, B., Sedel, F., Baron-Van Evercooren, A., & Mozafari, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415733 · Cited by 7
“The lack of promoting effect on myelination by human cells could explain why MD1003 failed in the SPI2 clinical trial study [32].”
BackgroundSelf-citationFrom insights to innovations: evaluating preclinical paradigms in demyelinating disease therapeutics
Karbalaee, M., Lin, A., Peruzzotti-Jametti, L., Pluchino, S., & Mozafari, S. (2026) · Lab Animal · doi:10.1038/s41684-026-01725-6 · Cited by 2
Metadata
- Authors
- Cree, B. A. C., Cutter, G., Wolinsky, J. S., Freedman, M. S., Comi, G., Giovannoni, G., Hartung, H.-P., Arnold, D., Kuhle, J., Block, V., Munschauer, F. E., Sedel, F., Lublin, F. D., Reingold, S., Duquette, P., Derfuss, T., Fazekas, F., Sormani, M. P., Lisak, R. P., Graves, J., Krieger, S., Zabad, R. K., Newsome, S., Barton, J., MacDonell, R., Marriott, M., De Klippel, N., Laureys, G., Willekens, B., Devonshire, V., Freedman, M., Girard, J. M., Giacomini, P., McKelvey, R., Selchen, D., Vorobeychik, G., Witkowski, L., Ampapa, R., Preiningerova, J. L., Meluzinova, E., Talab, R., Vachova, M., Aktas, O., Buttmann, M., Birte, E.-H., Kuempfel, T., Friedemann, P., Rau, D., Reifschneider, G., Sokolowski, P., Tumani, H., Satori, M., Pozzilli, C., Klosek, A., Koscielniak, J., Waldemar, F., Zajda, M., Gonzalez, R. A., Ayuso, G. I., Sanchez, V. F., Guevara, C. O., Rodriguez, J. E. M., Montalban, X., Ramio-Torrenta, L., Brundin, L., Lycke, J., Terzi, M., Guadagno, J., Mahad, D., Pace, A., Schmierer, K., Toosy, A., Webb, S., Agius, M., Amezcua, L., Apperson, M., Bagert, B., Bandari, D., Bernitsas, E., Calkwood, J., Carter, J., Cohen, B., Conway, D., Cooper, J., Corboy, J., Coyle, P., Cree, B., Freedman, M., Ford, C., Fox, E., Goldman, M., Greenberg, B., Kita, M., Leist, T., Lynch, S., Miller, A., Moses, H., Naismith, R., Picone, M. A., Perminder, B., Rae-Grant, A., Rammohan, K., Reder, A., Riley, C., Robertson, D., Rowe, V., Saidha, S., Samkoff, L., Severson, C., Smoot, K., Stoll, S., Trudell, R., Weinstock-Guttman, B., & Yathiraj, S.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 19
- Issue
- 12
- Pages
- 988-997
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W3094186674
- Cited by
- 108
- References
- 8
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1474-4422(20)30347-1
- The paper
- Cree, B. A. C., Cutter, G., Wolinsky, J. S., Freedman, M. S., Comi, G., Giovannoni, G., Hartung, H.-P., Arnold, D., Kuhle, J., Block, V., Munschauer, F. E., Sedel, F., Lublin, F. D., Reingold, S., Duquette, P., Derfuss, T., Fazekas, F., Sormani, M. P., Lisak, R. P., . . . Yathiraj, S. (2020). Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(20)30347-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.